Literature DB >> 14719840

Foot malignancies: a multidisciplinary approach.

Panayiotis J Papagelopoulos1, Andreas F Mavrogenis, Athanasios Badekas, Franklin H Sim.   

Abstract

Malignant osseous and soft tissue tumors of the foot are rare and should be considered in patients who have foot-related symptoms. Most sarcomas affect patients who are older than 55 years; however, many young patients who are otherwise healthy, may present with malignant foot and ankle lesions. In addition to benign and malignant neoplasms, pseudotumorous conditions mimic neoplastic lesions and should be differentiated before any treatment is undertaken. Invasiveness is a characteristic of sarcomas. The foot is a terminal anatomic structure, with closed and tight compartments and well-vascularized tissues, that predispose it to hematogenous and lymphatic metastases. Patients who have a malignant foot tumor should be referred to an orthopedic oncologist for further evaluation and treatment. The goals of treatment include local tumor control, restoration of function and stability during standing and walking, long-term survival, and improved quality of life. In most cases, wide surgical margins require a ray, Syme, midtarsal, or below-the-knee amputation. Recent advances in chemotherapy and radiotherapy have allowed limb salvage procedures with wide tumor resections. Because overall survival is greatly improved in these patients, the reconstruction of skeletal defects needs to be more functional and durable. After tumor resection, reconstruction of the skeletal and soft tissue defects is possible by using bone allografts or vascularized autografts, arthrodesis, and free vascularized musculocutaneous flaps.

Entities:  

Mesh:

Year:  2003        PMID: 14719840     DOI: 10.1016/s1083-7515(03)00150-5

Source DB:  PubMed          Journal:  Foot Ankle Clin        ISSN: 1083-7515            Impact factor:   1.653


  8 in total

1.  Autologous structural iliac bone grafts in reconstructions of short bone defects in the hand and foot after primary bone tumor resections: a single-institution retrospective study.

Authors:  J Lesensky; K Nemec; I Kofranek; Z Matejovsky
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-06-13

2.  Foot sarcomas: Factors affecting oncological and functional outcomes.

Authors:  Eiji Kozawa; Yoshihiro Nishida; Hiroatsu Nakashima; Satoshi Tsukushi; Kazuhiro Toriyama; Yuzuru Kamei; Naoki Ishiguro
Journal:  Oncol Lett       Date:  2011-09-22       Impact factor: 2.967

3.  In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy.

Authors:  F Russo; S Mazzetti; G Grignani; G De Rosa; M Aglietta; G C Anselmetti; M Stasi; D Regge
Journal:  Eur Radiol       Date:  2011-12-04       Impact factor: 5.315

4.  Lumps and bumps around the foot and ankle: an assessment of frequency with ultrasound and MRI.

Authors:  Akash Ganguly; Hifz Aniq; Bill Skiadas
Journal:  Skeletal Radiol       Date:  2013-02-06       Impact factor: 2.199

5.  The adverse effect of an unplanned surgical excision of foot soft tissue sarcoma.

Authors:  Akinobu Nishimura; Akihiko Matsumine; Kunihiro Asanuma; Takao Matsubara; Tomoki Nakamura; Atsumasa Uchida; Ko Kato; Akihiro Sudo
Journal:  World J Surg Oncol       Date:  2011-12-05       Impact factor: 2.754

6.  Limb salvage surgery following resection of a melanoma: Foot and ankle reconstruction using cutaneous flaps.

Authors:  Jian-Feng Liu; Li-Rong Zhao; Lai-Jin Lu; Lei Chen; Zhi-Gang Liu; Xu Gong; Bin Liu
Journal:  Oncol Lett       Date:  2014-08-12       Impact factor: 2.967

7.  Myositis ossificans: A rare location in the foot. Report of a case and review of literature.

Authors:  Qays Ahmed Hassan Al-Timimy; Mohammed Shehab Al-Edani
Journal:  Int J Surg Case Rep       Date:  2016-07-14

8.  Bufalin Induces Apoptosis of Human Osteosarcoma U-2 OS Cells through Endoplasmic Reticulum Stress, Caspase- and Mitochondria-Dependent Signaling Pathways.

Authors:  Ching-Hsiao Lee; Yung-Luen Shih; Mei-Hui Lee; Man-Kuan Au; Yung-Liang Chen; Hsu-Feng Lu; Jing-Gung Chung
Journal:  Molecules       Date:  2017-03-10       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.